檢索結果 - Denis Maillet

  • Showing 1 - 11 results of 11
Refine Results
  1. 1
    Ineffectiveness of Crizotinib on Brain Metastases in Two Cases of Lung Adenocarcinoma with EML4-ALK Rearrangement

    Ineffectiveness of Crizotinib on Brain Metastases in Two Cases of Lung Adenocarcinoma with EML4-ALK Rearrangement 由 Denis Maillet, Isabelle Martel‐Lafay, D. Arpin, M. Pérol

    出版 2013
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  2. 2
    A systematic review of adverse events in randomized trials assessing immune checkpoint inhibitors

    A systematic review of adverse events in randomized trials assessing immune checkpoint inhibitors 由 Patrick Arnaud‐Coffin, Denis Maillet, Hui Gan, Jean‐Jacques Stelmes, Benoît You, Stéphane Dalle, Julien Péron

    出版 2019
    獲取全文 獲取全文
    Revisão
    加到收藏夾
    Saved in:
  3. 3
    Renal adverse effects of immune checkpoints inhibitors in clinical practice: ImmuNoTox study

    Renal adverse effects of immune checkpoints inhibitors in clinical practice: ImmuNoTox study 由 Maxime Espi, Cécile Teuma, Etienne Novel-Catin, Denis Maillet, P.-J. Souquet, Stéphane Dalle, Laetitia Koppe, Denis Fouque

    出版 2021
    獲取全文
    Artigo
    加到收藏夾
    Saved in:
  4. 4
    Older and younger patients treated with immune checkpoint inhibitors have similar outcomes in real-life setting

    Older and younger patients treated with immune checkpoint inhibitors have similar outcomes in real-life setting 由 Pauline Corbaux, Denis Maillet, Amélie Boespflug, M. Locatelli-Sanchez, Marie Perier‐Muzet, M. Duruisseaux, Lize Kiakouama-Maleka, Stéphane Dalle, Claire Falandry, Julien Péron

    出版 2019
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  5. 5
    Association between immune-related adverse events and long-term survival outcomes in patients treated with immune checkpoint inhibitors

    Association between immune-related adverse events and long-term survival outcomes in patients treated with immune checkpoint inhibitors 由 Denis Maillet, Pauline Corbaux, Jean‐Jacques Stelmes, Stéphane Dalle, M. Locatelli-Sanchez, Marie Perier‐Muzet, M. Duruisseaux, Lize Kiakouama-Maleka, Gilles Freyer, Amélie Boespflug, Julien Péron

    出版 2020
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  6. 6
    Tolerability of Olaparib Combined with Abiraterone in Patients with Metastatic Castration-resistant Prostate Cancer: Further Results from the Phase 3 PROpel Trial

    Tolerability of Olaparib Combined with Abiraterone in Patients with Metastatic Castration-resistant Prostate Cancer: Further Results from the Phase 3 PROpel Trial 由 Fred Saad, Andrew J. Armstrong, Mototsugu Oya, Karina Vianna, Mustafa Özgüroğlu, Craig Gedye, Gary L. Buchschacher, Ji Youl Lee, Urban Emmenegger, Jiří Navrátil, Juan Antonio Virizuela, Aníbal Salazar, Denis Maillet, Hiroji Uemura, Jeri Kim, Emma Oscroft, Laura Barker, Arnold Degboe, Noel W. Clarke

    出版 2024
    獲取全文
    Artigo
    加到收藏夾
    Saved in:
  7. 7
    BAP1 Is Altered by Copy Number Loss, Mutation, and/or Loss of Protein Expression in More Than 70% of Malignant Peritoneal Mesotheliomas

    BAP1 Is Altered by Copy Number Loss, Mutation, and/or Loss of Protein Expression in More Than 70% of Malignant Peritoneal Mesotheliomas 由 Noémie Leblay, Frédéric Leprêtre, Nolwenn Le Stang, Amandine Gautier‐Stein, Laurent Villeneuve, Sylvie Isaac, Denis Maillet, Françoise Galateau-Sallé, Céline Villenet, Shéhérazade Sebda, Alexandra Goracci, Graham Byrnes, James McKay, Martin Figeac, Olivier Gléhen, François-Noël Gilly, Matthieu Foll, Lynnette Fernandez‐Cuesta, Marie Brevet

    出版 2016
    獲取全文
    Artigo
    加到收藏夾
    Saved in:
  8. 8
    Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial

    Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial 由 Thomas Powles, Mark Kockx, Alejo Rodríguez‐Vida, Ignacio Durán, Simon J. Crabb, Michiel S. van der Heijden, Bernadett Szabados, Albert Font Pous, Gwénaëlle Gravis, Urbano Anido, Andrew Protheroe, Alain Ravaud, Denis Maillet, María José Méndez, Cristina Suárez, Mark Linch, Aaron Prendergast, Pieter‐Jan van Dam, Diana Stanoeva, Sofie Daelemans, Sanjeev Mariathasan, Joy S. Tea, Kelly Mousa, Romain Banchereau, Daniel Castellano

    出版 2019
    獲取全文
    Artigo
    加到收藏夾
    Saved in:
  9. 9
    Diagnostic and prognostic biomarkers in immune checkpoint inhibitor-related encephalitis: a retrospective cohort study

    Diagnostic and prognostic biomarkers in immune checkpoint inhibitor-related encephalitis: a retrospective cohort study 由 Antonio Farina, Macarena Villagrán‐García, Anthony Fourier, Anne‐Laurie Pinto, Fatima Chorfa, Noémie Timestit, Tifanie Alberto, Jérôme Aupy, Marie Bénaiteau, Cristina Birzu, Lucia Campetella, François Cotton, Stéphane Dalle, Clara Fontaine Delaruelle, Pauline Dumez, Rafaele Germi, Marion Le Maréchal, Denis Maillet, Romain Marignier, Antoine Pégat, Dimitri Psimaras, Marie Rafiq, Géraldine Picard, Virginie Desestret, Isabelle Quadrio, Jérôme Honnorat, Bastien Joubert

    出版 2024
    獲取全文
    Artigo
    加到收藏夾
    Saved in:
  10. 10
    Final Results of Neoadjuvant Atezolizumab in Cisplatin-ineligible Patients with Muscle-invasive Urothelial Cancer of the Bladder

    Final Results of Neoadjuvant Atezolizumab in Cisplatin-ineligible Patients with Muscle-invasive Urothelial Cancer of the Bladder 由 Bernadett Szabados, Mark Kockx, Zoe J. Assaf, Pieter‐Jan van Dam, Alejo Rodríguez‐Vida, Ignacio Durán, Simon J. Crabb, Michiel S. van der Heijden, Albert Font Pous, Gwénaëlle Gravis, Urbano Anido Herranz, Andrew Protheroe, Alain Ravaud, Denis Maillet, María José Méndez, Cristina Suárez, Mark Linch, Aaron Prendergast, Charlotte Tyson, Diana Stanoeva, Sofie Daelemans, Miche Rombouts, Sanjeev Mariathasan, Joy S. Tea, Kelly Mousa, Shruti Sharma, Alexey Aleshin, Romain Banchereau, Daniel Castellano, Thomas Powles

    出版 2022
    獲取全文
    Artigo
    加到收藏夾
    Saved in:
  11. 11
    Nivolumab, nivolumab–ipilimumab, and VEGFR-tyrosine kinase inhibitors as first-line treatment for metastatic clear-cell renal cell carcinoma (BIONIKK): a biomarker-driven, open-label, non-comparative, randomised, phase 2 trial

    Nivolumab, nivolumab–ipilimumab, and VEGFR-tyrosine kinase inhibitors as first-line treatment for metastatic clear-cell renal cell carcinoma (BIONIKK): a biomarker-driven, open-lab... 由 Yann Vano, Réza Elaidi, Mostefa Bennamoun, Christine Chevreau, Delphine Borchiellini, Diane Pannier, Denis Maillet, Marine Gross‐Goupil, Christophe Tournigand, Brigitte Laguerre, Philippe Barthélémy, Elodie Coquan, Gwénaëlle Gravis, Nadine Houédé, Mathilde Cancel, Olivier Huillard, Philippe Beuzeboc, Laure Fournier, Arnaud Méjean, Xavier Cathelineau, N. Doumerc, P. Paparel, Jean‐Christophe Bernhard, Alexandre de la Taille, Karim Bensalah, Thibault Tricard, Thibaut Waeckel, G. Pignot, E. Braychenko, Stefano Caruso, Cheng‐Ming Sun, Virginie Verkarre, Guillaume Lacroix, Marco Moreira, Maxime Meylan, Antoine Bougoüin, Letuan Phan, Christelle Thibault-Carpentier, Jessica Zucman‐Rossi, Wolf H. Fridman, Catherine Sautès‐Fridman, Stéphane Oudard

    出版 2022
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:

檢索工具: